1. Ding, K.#, Zhu, Y.#, Yan, L.#, Zhu, L., Zhang, T., Zhang, R., Li, Q., Xie, B., Ding, L., Shang, L., Wang, Y., Xu, P., Zhu, T.*, Chen, C.*, & Zhu, Y.* (2024). Multiwalled Carbon Nanotubes-Reprogrammed Macrophages Facilitate Breast Cancer Metastasis via NBR2/TBX1 Axis. ACS nano, 10.1021/acsnano.3c11651. (期刊论文)
2. Ding, L.#, Jiang, H.#, Li, Q.#, Li, Q., Zhang, T. T., Shang, L., Xie, B., Zhu, Y., Ding, K., Shi, X.*, Zhu, T.*, & Zhu, Y*. (2024). Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancer. Journal of experimental & clinical cancer research : CR, 43(1), 90. (期刊论文)
3. Zhu, Y. #, Shang, L. #, Tang, Y. #, Li, Q., Ding, L., Wang, Y., Zhang, T., Xie, B., Ma, J., Li, X., Chen, S., Yi, X., Peng, J., Liang, Y., He, A., Yan, H., Zhu, H. *, Zhang, B. *, & Zhu, Y *. (2024). Genome-Wide Profiling of H3K27ac Identifies TDO2 as a Pivotal Therapeutic Target in Metabolic Associated Steatohepatitis Liver Disease. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e2404224. (期刊论文)
4. Zhang, R. #, Wang, Z. #, Wang, H. #, Li, L., Dong, L., Ding, L., Li, Q., Zhu, L., Zhang, T., Zhu, Y. *, & Ding, K. * (2024). CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma. Biomolecules & biomedicine, 25(1), 42–61. (期刊论文)
5. Zhu, L., Zhu, H., Zhang, Z., Xu, F., Zhu, Y. *, & Ding, K. * (2025). A Novel Prognostic Model of Endometrial Cancer Based on Inflammation and Lipid Metabolism Genes. Genetic testing and molecular biomarkers, 29(8), 216–231. (期刊论文)
6. Lu, X.#, Zhu, Y.#, Bai, R., Wu, Z., Qian, W., Yang, L., Cai, R., Yan, H., Li, T., Pandey, V., Liu, Y., Lobie, P. E., Chen, C.*, & Zhu, T*. (2019). Long-term pulmonary exposure to multi-walled carbon nanotubes promotes breast cancer metastatic cascades. Nature nanotechnology, 14(7), 719–727. (期刊论文)
7. Zhang, Y.#, Sun, Y.#, Ding, L., Shi, W., Ding, K., & Zhu, Y*. (2021). Long Non-Coding RNA LINC00467 Correlates to Poor Prognosis and Aggressiveness of Breast Cancer. Frontiers in oncology, 11, 643394. (期刊论文)
8. Zhu, Y.#, Zhang, R.#, Zhang, Y., Cheng, X., Li, L., Wu, Z.*, & Ding, K*. (2021). NUDT21 Promotes Tumor Growth and Metastasis Through Modulating SGPP2 in Human Gastric Cancer. Frontiers in oncology, 11, 670353. (期刊论文)
9. Zhu, Y., Yang, L., Chong, Q. Y., Yan, H., Zhang, W., Qian, W., Tan, S., Wu, Z., Lobie, P. E.*, & Zhu, T*. (2019). Long noncoding RNA Linc00460 promotes breast cancer progression by regulating the miR-489-5p/FGF7/AKT axis. Cancer management and research, 11, 5983–6001. (期刊论文)
10. Yuan, H.#, Yan, L.#, Wu, M., Shang, Y., Guo, Q., Ma, X., Zhang, X., Zhu, Y., Wu, Z., Lobie, P. E.*, & Zhu, T*. (2022). Analysis of the Estrogen Receptor-Associated LncRNA Landscape Identifies a Role for ERLC1 in Breast Cancer Progression. Cancer research, 82(3), 391–405. (期刊论文)
11. Yang, L.#, Wang, M.#, Wang, Y., Zhu, Y., Wang, J., Wu, M., Guo, Q., Han, X., Pandey, V., Wu, Z., Lobie, P. E.,* & Zhu, T*. (2024). LINC00460-FUS-MYC feedback loop drives breast cancer metastasis and doxorubicin resistance. Oncogene, 10.1038/s41388-024-02972-y. (期刊论文)
12. Tan, S.#, Li, H.#, Zhang, W.#, Shao, Y., Liu, Y., Guan, H., Wu, J., Kang, Y., Zhao, J., Yu, Q., Gu, Y., Ding, K., Zhang, M., Qian, W., Zhu, Y., Cai, H., Chen, C., Lobie, P. E., Zhao, X.*, Sun, J.*, Zhu, T*. (2018). NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression. Oncogene, 37(35), 4887–4900. (期刊论文)